Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy
https://www.benzinga.com/pressreleases/19/10/ac14609413/mymetics-announces-new-study-to-predict-efficacy-of-second-generation-cop-allergy-immunotherpy-wi?utm_campaign=Watchlist&utm_source=Benzinga&utm_medium=Email
Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes
ACCESSWIRE FOLLOW
October 17, 2019 6:00am Comments
- The second-generation Allergen Immunotherapy based on Anergis Continous Overlapping Peptides (COP) linked to Mymetics Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch allergy
- Results of the study are expected in Q1 2020
EPALINGES, SWITZERLAND / ACCESSWIRE / October 17, 2019 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT), and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), announced the start of a new research study to evaluate the effects of the second generation virosome- based COP allergen immunotherapy in a therapeutic model of birch allergy in mice. The aim is to shorten the AIT administration scheme.
The research collaboration combines the ultra-fast AIT approach developed by Anergis and Mymetics, namely the second-generation of COP allergen immunotherapy based on Anergis COPs and Mymetics virosomes (COP-Virosomes), with the longstanding know-how of Stallergenes Greer.
In December 2018, Anergis and Mymetics reported that the COP-Virosomes were able to elicit a strong boost in TH1 antibody response without any IgE response, unlike the first generation of Anergis' COPs associated with aluminum hydroxide.
Stallergenes Greer will now test the COP-Virosomes in the therapeutic mouse model of birch allergy in comparison with positive controls, i.e,. birch allergen and birch pollen extract. This model has been confirmed as having predictive value towards the future clinical efficacy of new AIT treatment candidates.
"We are excited to launch this new study and eager to demonstrate the potential of COP-Virosomes as a breakthrough AIT treatment of the future. The Stallergenes Greer therapeutic model mimics specific immune responses to birch pollen from allergic individuals and should provide evidence of COP-Virosomes potential," said Vincent Charlon, CEO of Anergis.
"We are very encouraged to see that on the basis of the results from the 2018 preclinical program, Stallergenes Greer sees great potential from the COP-Virosomes allergy treatment, and we look forward to the results of this study" said Ronald Kempers, CEO of Mymetics.
About Mymetics
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation
preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, malaria, Chikungunya and the RSV vaccine in addition to several ongoing collaborative projects in the field of allergy and oncology Immunotherapy.
Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigen and adjuvants. For further information, please visit www.mymetics.com.
Contacts:
Mymetics Corporation
Ronald Kempers, CEO
Tel: +41 21 653 4535 / info@mymetics.com
Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
SOURCE: Mymetics Corporation
Love your enthusiasm and thanks a million for sharing your findings and for connecting the dots for all of us.
Nicely done!
Hang tough, you say?
Man, I ain't going nowhere... In fact, i call this my other 401k, come what may
I am planning to load more as the opportunity presents itself, and I usually don't hesitate in slapping the ask.
Cheers!
Got almost 70k at ask
Mofos wouldn't fill my large order i need to see someone in my office...
Bought more at .04 today
Mymetics receives HIV Vaccine Funding from the NIH - Funding to prepare Mymetics' cold chain independent needle free mucosal virosome HIV vaccine candidate for clinical trials - Collaboration with Texas Biomedical Research Institute and University of Louisiana at Lafayette
- Total award USD 8.5 million over 5 years, with USD 1.9 million budget in the first year
https://www.prnewswire.com/news-releases/mymetics-receives-hiv-vaccine-funding-from-the-nih-300839336.html
PR Newswire EPALINGES, Switzerland, April 29, 2019 EPALINGES, Switzerland, April 29, 2019 /PRNewswire/ -- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the National Institutes of Health (NIH) has awarded Mymetics and Texas Biomedical Research Institute (Texas Biomed) a five-year grant for the project called "Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels". The project has the objective to prepare Mymetics' promising HIV-1 vaccine candidate for clinical trials. The vaccine candidate is based upon Mymetics' virosomes, enveloped virus-like particles that display on their surface rationally designed HIV-1 antigens. The vaccine is created to induce protective mucosal antibodies acting as a frontline defense against sexual HIV transmission. An earlier formulation of the vaccine candidate has shown safety and immunogenicity in a Phase I clinical trial in healthy women. Two independent non-human primate studies demonstrated the safety and high efficacy of the virosome-based vaccine in Chinese and Indian-origin rhesus macaques against repeated low-dose intravaginal challenges with a monkey AIDS virus, a so-called tier 2 R5 SHIV that shares key biological features with transmitted forms of HIV-1. Mymetics recently finished a European Horizon 2020 funded project, where Mymetics developed adjuvanted new solid powder forms of the vaccine, which can be directly administered to mucosal tissues (nose, sublingual or oral) without needles and that do not depend on refrigeration, which makes the new vaccine attractive for the developing world where AIDS is at epidemic levels. "We are excited to collaborate with Mymetics and our partners on a promising AIDS vaccine candidate that seeks to induce protective immune defenses at mucosal barriers -- where HIV-1 first enters the body during sexual transmission of HIV-1. The new joint project complements our basic research, where we demonstrated potent protection with mucosal antibodies administered to rhesus macaques," said Professor and Director of the Texas Biomed AIDS Program, Dr. Ruth Ruprecht, who serves as Principal Investigator together with Dr. Sylvain Fleury, CSO of Mymetics Corporation. "We are extremely grateful for the trust and support from the NIH for our project, it will enable the continued progress of our cold chain, independent virosome based HIV vaccine candidate," Ronald Kempers, CEO of Mymetics, stated. "We will be able to prepare it for clinical trials in collaboration with world leading HIV scientists from the University of Louisiana at Lafayette and our longstanding partner Texas Biomed." The project will start on May 1, 2019 and is planned for five years. It is co-led by Drs. Ruprecht and Fleury and includes subawards to Dr. Fran?ois Villinger of the University of Louisiana at Lafayette, and Dr. Sarah Ratcliffe of the University of Virginia. First results are expected to be reported in 2020. About Mymetics Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, malaria, Chikungunya and the RSV vaccine in addition to several ongoing collaborative projects in the field of allergy and oncology Immunotherapy. Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigen and adjuvants. For further information, please visit www.mymetics.com. About Texas Biomed Texas Biomedical Research Institute is one of the world's leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. Located on a 200-acre campus on the northwest side of San Antonio, Texas, the Institute partners with hundreds of researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, herpes, hemorrhagic fevers, and parasitic diseases responsible for malaria, schistosomiasis and Chagas disease. The Institute also has programs in the genetics of cardiovascular disease, diabetes, obesity, psychiatric disorders and other diseases. For more information on Texas Biomed, go to www.TxBiomed.org. About NIH and NIAID This research is being supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI142636. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Forward looking statements The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made. View original content:http://www.prnewswire.com/news-releases/mymetics-receives-hiv-vaccine-funding-from-the-nih-300839336.html SOURCE Texas Biomedical Research Institute /CONTACT: Mymetics Corporation, Ronald Kempers, CEO, +41 21 653 4535, info@mymetics.com, Texas Biomedical Research Institute, Lisa Cruz, Director of Public Relations, San Antonio, TX, USA, Work: 210-258-9437, Cell: 210-724-1691, Email: lcruz@txbiomed.org /Web site: http://www.TxBiomed.org (END) Dow Jones Newswires April 29, 2019 08:00 ET (12:00 GMT) Story ID: 20190429DN004694 Keywords: COMPANY NEWS, THIRD-PARTY CONTENT, PRESS RELEASES AUTO-PUBLISHED ON TICKER, DOW JONES EUROPEAN INVESTMENT NEWS, DOW JONES EUROPEAN PREMIUM INVESTMENT NEWS, DOW JONES CONTENT SET DN, FINANCING AGREEMENTS, DOW JONES PORTFOLIO NEWS, HEALTH CARE, DOW JONES GLOBAL MARKETS NEWS, DOW JONES ADVISOR MARKETS, DOW JONES GLOBAL PREMIUM INVESTMENT NEWS, DOW JONES EQUITY TRADING NORTH AMERICA, PRESS RELEASES ON NEWSWIRES, GRAND CENTRAL ASSET CLASS EQUITIES, GLOBAL EQUITIES SPOTLIGHT, SIGNIFICANT STORY, CORPORATE ACTIONS, DOW JONES INTERNATIONAL NEWS SERVICE, OFF-TRADING FLOOR INVESTMENT NEWS, EQUITY TRADER EUROPE, DOW JONES GLOBAL EQUITIES NEWS, OFF-TRADING FLOOR PORTFOLIO NEWS, DOW JONES GLOBAL INVESTMENT NEWS, DOW JONES NEWS SERVICE, BIOTECHNOLOGY, DOW JONES NEWS WIRES Symbols: MYMX
Yup, I think Anergis deal is just around the corner.
Someone call security please!
Bill Gates
?
Verified account
@BillGates
Follow Follow @BillGates
More
The good news is that there has been progress toward a vaccine that would protect you from every possible strain of the flu. But the world still needs to develop a global system for responding to epidemics.
8:59 AM - 30 Dec 2018
NICE!!!!
Hello everyone! Wishing you all lots of success and mymx riches for 2019! BRING IT ON!
There are "no buyers here either" because many who find this don't do the necessary due diligence to understand what's actually happening here and walk away thinking that there's nothing going on. There is a lot happening here and you just have to spend some time going through some posts that will shed light into the opportunity that does not come by so frequently. We all are lucky to have found this gem at these levels because when things materialize, and there is a reason to expect that very soon, then this will have left the station making only express stops.
Of course, it is then when people (perhaps including you, if the shoe fits) will start chasing it to our benefit and we thank you for that in advance.
Alternatively, people can sign up for email alerts which will alert all interested parties 2 weeks before this takes off. Wouldn't life be perfect if that was really true...
All said and done, I wish you all the best with your investment decisions.
Happy NYE!
Prayers for bow-tie and please extend my best wishes to him... Happy 2019 to all here, as well...
Happy Holidays everyone!
The Patent Trial and Appeal Board Gives Voip-Pal Another Significant Victory by Declining to Impose Apple's Requested Sanctions Against Them
https://www.benzinga.com/pressreleases/18/12/g12894774/the-patent-trial-and-appeal-board-gives-voip-pal-another-significant-v
Let's play a game...
Your PT for end of year is _________?
My PT is .18
Someone trying to shake the tree...
So they can explain why they are selling for pennies when they could potentially get dollar(s) and also so I can suspend their trading privileges
I'd like to see the sellers in my office NOW
HH thank you for posting such awesome DD. Much appreciated man... I am sure you saw today's news by now
If I had to guess then Anergis probably has anywhere from 30 to 90 days to license Mymetics' virosome technology before MYMX goes to the next highest bidder...
Mymetics Virosomes Successful in Allergy Proof-of-Concept Study
ACCESSWIRE
December 13, 2018 2:00am
Success criteria met: Bet v 1 COP-virosomes showed no IgE induction, favorable TH1 response and were well tolerated in mice study
Anergis has time limited exclusive option to license Mymetics' virosome technology in the field of allergies
EPALINGES, SWITZERLAND / ACCESSWIRE / December 13, 2018 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the pre-clinical proof-of-concept study for allergies, with their partner Anergis SA, has met the success criteria.
The mice proof-of-concept immunogenicity study evaluated the effects of the Bet v 1 COPs (Anergis' proprietary birch pollen allergy peptides) using the five subcutaneous injection schedule used in former AllerT clinical trials. The development of AllerT (Bet v 1 COPs plus aluminum hydroxide) was discontinued by Anergis in 2017 following completion of a Phase 2 clinical trial showing evidence of sensitization to the peptides and a 7% reduction in seasonal allergy symptoms vs placebo (p=0.0047).
In the mice study, AllerT was compared to Bet v 1 COPs linked to Mymetics' virosomes (the "Bet v 1 COP-virosomes"). Anergis reported that the administration of AllerT led to the development of Bet v 1 specific IgEs (p<0.001) associated with a more pronounced TH2 than TH1 response. In contrast, in the mice receiving the Bet v 1 COP-virosomes, no development of Bet v 1 specific IgEs were observed (p<0.001 vs AllerT). With the same dose of Bet v 1 COPs, there was a strong boost of immunogenicity with a TH1 antibody response, which was a hundred times greater than with aluminum hydroxide (p<0.001). The Bet v 1 COP-virosomes were well tolerated.
This study is part of the research collaboration agreement between Anergis and Mymetics which was signed in April 2018. The success criteria were met and Anergis has now a time limited option to enter into an exclusive license agreement with Mymetics for the use of virosomes in the field of allergies.
Ronald Kempers, CEO of Mymetics, stated: "The results from Anergis are very encouraging and show that our virosomes can have a broad application in vaccines, not only for prevention of infectious diseases but also in the field of immunotherapy for allergies."
About Mymetics
Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, malaria, Chikungunya and the RSV vaccine and several ongoing collaborative projects in the field of allergy and oncology Immunotherapy.
Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. For further information, please visit www.mymetics.com.
CONTACT:
Mymetics Corporation
Ronald Kempers, CEO
Tel: +41 21 653 4535 / info@mymetics.com
Forward looking statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
SOURCE: Mymetics Corporation
I am eagerly waiting for that as this brother got big dreams!
Man, just Moderna's IPO itself should have gotten mymx some love but I guess the problem is not many know about mymx.
Maybe we all should chip in and start a Google ad campaign to make this board pop up on top of searches for anything searched using "mRNA" - lol
Looks halted for volatility...
or it's just extended Day of Mourning for GHW Bush
MYMX is on the RIGHT TRACK...
Oct 16th PR says...
https://www.biospace.com/article/mymetics-starts-research-collaboration-project-in-cancer-immunotherapy-with-etherna/
The project is the first step in determining if there is a basis for a further collaboration between Mymetics and eTheRNA.
“We have been interested in further evaluating Mymetics’ virosomes in cancer immunotherapies for a while, so we look forward to work with eTheRNA in this explorative project to evaluate their innovative mRNA constructs in combination with our virosomes and to test the efficacy in tumor models,” stated Ronald Kempers, CEO of Mymetics Corporation.
“mRNA-based therapies have a unique potential to enhance cancer immunotherapy. For mRNA to reach its target, the cellular cytosol and have an optimal effect, the selection of an appropriate delivery vehicle is key. As viruses have evolved highly effective mechanisms to deliver their nucleic acids across cellular membranes, we believe Mymetics’ virosomes might synergize with our mRNA platform and thus further boost the potency of eTheRNA’s mRNA immunotherapies,” stated Peter Tomme, head of preclinical development of eTheRNA.
===============================================
Moderna IPO'd today...
https://www.fiercebiotech.com/biotech/moderna-s-cash-juggernaut-rolls-record-604m-ipo
Moderna’s core technology uses mRNA to spur the production of human proteins within patient cells, creating what the company describes as an in vivo "factory" for targeted therapies.
The biotech will certainly need its deep pockets as strives to advance is 21 mRNA-based pipeline programs—spanning infectious diseases, immuno-oncology and rare diseases—through clinical development and toward the market.
I am with you on that HH... In fact, this time around, I even have my toes crossed in addition to my fingers!
only 85K at .07 then 331K at .0972... come on... let's GO!
I just love your excitement... lol
WOOOOOHOOO INDEED!
Saw that... low volume day today.. 12K, last trade of 5k at .06498
Yeah, let's go and then only 70K at .07
Eturd no longer on the ask, only cdel with 126K at .065
I am already imagining this at .65 at least
271K wall at .065... wtf?
let it go...
Man, this stock looks so ready to rock-n-roll... Wonder who is holding this up and why
Daily chart looking very good, MACD now above the 0 level, RSI and MFI also looking bullish.
How can all that be short volume? It looked like mostly buys yesterday hence the closing of .065... Am I missing something?
I guess someone desperately needed $63.80 (1k sold at .0638)... Dear God!
Evidently, most of us have found compelling reasons to believe in the "what ifs" thus also putting the Law of Attraction to the test... Think and Grow Rich, my friend... Best wishes for all!
Man, that looks sweet... bring it on!